175 related articles for article (PubMed ID: 29888758)
21. Clinical and genomic characterization of mutational signatures across human cancers.
Liao J; Bai J; Pan T; Zou H; Gao Y; Guo J; Xu Q; Xu J; Li Y; Li X
Int J Cancer; 2023 Apr; 152(8):1613-1629. PubMed ID: 36533638
[TBL] [Abstract][Full Text] [Related]
22. Influence network model uncovers relations between biological processes and mutational signatures.
Amgalan B; Wojtowicz D; Kim YA; Przytycka TM
Genome Med; 2023 Mar; 15(1):15. PubMed ID: 36879282
[TBL] [Abstract][Full Text] [Related]
23. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
24. Patterns and processes of somatic mutations in nine major cancers.
Jia P; Pao W; Zhao Z
BMC Med Genomics; 2014 Feb; 7():11. PubMed ID: 24552141
[TBL] [Abstract][Full Text] [Related]
25. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
26. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
[TBL] [Abstract][Full Text] [Related]
27. Error-free versus mutagenic processing of genomic uracil--relevance to cancer.
Krokan HE; Sætrom P; Aas PA; Pettersen HS; Kavli B; Slupphaug G
DNA Repair (Amst); 2014 Jul; 19():38-47. PubMed ID: 24746924
[TBL] [Abstract][Full Text] [Related]
28. APOBEC mutagenesis is low in most types of non-B DNA structures.
Ponomarev GV; Fatykhov B; Nazarov VA; Abasov R; Shvarov E; Landik NV; Denisova AA; Chervova AA; Gelfand MS; Kazanov MD
iScience; 2022 Jul; 25(7):104535. PubMed ID: 35754742
[TBL] [Abstract][Full Text] [Related]
29. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.
Roberts SA; Lawrence MS; Klimczak LJ; Grimm SA; Fargo D; Stojanov P; Kiezun A; Kryukov GV; Carter SL; Saksena G; Harris S; Shah RR; Resnick MA; Getz G; Gordenin DA
Nat Genet; 2013 Sep; 45(9):970-6. PubMed ID: 23852170
[TBL] [Abstract][Full Text] [Related]
30. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
[TBL] [Abstract][Full Text] [Related]
31. The clock-like accumulation of germline and somatic mutations can arise from the interplay of DNA damage and repair.
Spisak N; de Manuel M; Milligan W; Sella G; Przeworski M
PLoS Biol; 2024 Jun; 22(6):e3002678. PubMed ID: 38885262
[TBL] [Abstract][Full Text] [Related]
32. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
[TBL] [Abstract][Full Text] [Related]
33. Disentangling sources of clock-like mutations in germline and soma.
Spisak N; de Manuel M; Milligan W; Sella G; Przeworski M
bioRxiv; 2023 Sep; ():. PubMed ID: 37745549
[TBL] [Abstract][Full Text] [Related]
34. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
[TBL] [Abstract][Full Text] [Related]
35. Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus.
Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Kurlander R; Patterson AP
J Biol Chem; 2017 Aug; 292(32):13459-13479. PubMed ID: 28637869
[TBL] [Abstract][Full Text] [Related]
36. APOBEC and ADAR deaminases may cause many single nucleotide polymorphisms curated in the OMIM database.
Lindley RA; Hall NE
Mutat Res; 2018 Jul; 810():33-38. PubMed ID: 29957488
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.
Beale RC; Petersen-Mahrt SK; Watt IN; Harris RS; Rada C; Neuberger MS
J Mol Biol; 2004 Mar; 337(3):585-96. PubMed ID: 15019779
[TBL] [Abstract][Full Text] [Related]
38. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
39. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
40. Experimental systems for the analysis of mutational signatures: no 'one-size-fits-all' solution.
Ivanov D; Hwang T; Sitko LK; Lee S; Gartner A
Biochem Soc Trans; 2023 Jun; 51(3):1307-1317. PubMed ID: 37283472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
